文献速递脑血管病

双联与单联抗血小板治疗在轻中度缺血性卒中中的比较:ATAMIS随机试验的事后分析

Dual Versus Mono Antiplatelet Therapy in Mild Versus Moderate Ischemic Stroke: A Post Hoc Analysis of the ATAMIS Randomized Trial
RSS 订阅 · Stroke

该研究为ATAMIS试验的预设事后分析,纳入2915例急性轻中度缺血性卒中患者,按NIHSS 4-5分(轻度,1992例)和6-10分(中度,923例)分组。结果显示,氯吡格雷联合阿司匹林较单用阿司匹林显著降低中度卒中组7天早期神经功能恶化风险(aOR 0.31,95%CI 0.17-0.59,P<0.001),而轻度组无显著差异(aOR 0.96,95%CI 0.66-1.41,P=0.841),交互作用P=0.003,出血事件两组相似。

要点

  • 中度卒中(NIHSS 6-10)双抗显著降低7天早期神经功能恶化风险。
  • 轻度卒中(NIHSS 4-5)双抗与单抗无显著差异。
  • 两严重度亚组出血事件和颅内出血均相似。

核心结论

  • 在急性轻中度缺血性卒中患者中,氯吡格雷联合阿司匹林较单用阿司匹林预防7天早期神经功能恶化的获益可能在中度卒中(NIHSS 6-10)患者中大于轻度卒中(NIHSS 4-5)患者,且不增加出血风险。
  • 基线卒中严重程度可能有助于指导抗血小板治疗选择,需未来前瞻性研究确认。

研究设计与样本

  • ATAMIS试验的预设事后分析,使用改良意向治疗人群数据。
  • 共纳入2915例患者,其中轻度卒中(NIHSS 4-5)1992例(68.4%),中度卒中(NIHSS 6-10)923例(31.6%)。
  • 中位年龄66岁(四分位距59-73),女性占35.0%。
  • 采用二元逻辑回归、Cox回归和广义线性模型,调整年龄、性别、糖尿病、高血压、发病至治疗时间、卒中病因等变量。
  • 评估治疗与基线卒中严重程度的交互作用。

主要发现

  • 中度卒中组:氯吡格雷联合阿司匹林较单用阿司匹林显著降低7天早期神经功能恶化风险(调整OR 0.31,95%CI 0.17-0.59;P<0.001)。
  • 轻度卒中组:氯吡格雷联合阿司匹林与单用阿司匹林无显著差异(调整OR 0.96,95%CI 0.66-1.41;P=0.841)。
  • 治疗效应与NIHSS亚组间存在显著交互作用(P交互=0.003)。
  • 两个严重度亚组中,出血事件和颅内出血发生率在治疗组间相似。

关键数值与推荐

  • 早期神经功能恶化定义为7天内NIHSS评分较基线增加≥2分。
  • 安全性结局包括90天内出血事件和颅内出血。
  • 轻度卒中定义为NIHSS评分4-5分,中度卒中定义为NIHSS评分6-10分。

临床怎么用

  • 对于急性中度缺血性卒中(NIHSS 6-10)患者,可考虑氯吡格雷联合阿司匹林以降低早期神经功能恶化风险。
  • 对于急性轻度缺血性卒中(NIHSS 4-5)患者,双联抗血小板治疗未显示显著获益,需个体化决策。
  • 基线卒中严重程度可作为抗血小板治疗方案选择的参考因素。

局限性

  • 为事后分析,结果需前瞻性研究确认。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stroke, Ahead of Print. BACKGROUND:This prespecified post hoc analysis of the ATAMIS trial (Antiplatelet Therapy in Acute Mild to Moderate Ischemic Stroke) aimed to investigate whether the benefit of dual antiplatelet therapy versus aspirin alone differs in patients with mild versus moderate stroke.METHODS:Using data from the modified intention‑to‑treat population of the ATAMIS trial, eligible patients were divided into mild (National Institutes of Health Stroke Scale [NIHSS] score 4–5) and moderate (NIHSS score 6–10) groups. The primary outcome was early neurological deterioration at 7 days, defined as an increase in the NIHSS score of ≥2 points from baseline. Safety outcomes included bleeding events and intracranial hemorrhage within 90 days. Binary logistic regression, Cox regression, and generalized linear models were used as appropriate. Adjusted models included age, sex, diabetes, hypertension, onset-to-treatment time, stroke cause, and other imbalanced baseline variables. Treatment-by-baseline stroke severity interaction was assessed.RESULTS:A total of 2915 patients were included, including 1992 (68.4%) with mild stroke and 923 (31.6%) with moderate stroke. Median age was 66 years (interquartile range, 59–73); 35.0% were women. Clopidogrel plus aspirin was associated with a significantly lower risk of early neurological deterioration compared with aspirin alone in the moderate stroke group (adjusted odds ratio, 0.31 [95% CI, 0.17–0.59];P<0.001), whereas no significant difference was observed in the mild stroke group (adjusted odds ratio, 0.96 [95% CI, 0.66–1.41];P=0.841). A significant interaction was identified between treatment effect and NIHSS score subgroup (Pinteraction=0.003). The occurrence of bleeding events and intracranial hemorrhage was similar between treatment groups in both severity subgroups.CONCLUSIONS:In patients with acute mild-to-moderate ischemic stroke, the benefit of clopidogrel plus aspirin versus aspirin alone in preventing early neurological deterioration at 7 days may be greater among patients with moderate stroke (NIHSS score 6–10) than among those with mild stroke (NIHSS score 4–5), without an increased risk of bleeding. These findings suggest that baseline stroke severity may inform antiplatelet therapy selection, and warrant confirmation in future prospective studies.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT02869009.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Stroke:Dual Versus Mono Antiplatelet Therapy in Mild Versus Moderate Ischemic Stroke: A Post Hoc Analysis of the ATAMIS Randomized Trial

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。